Things to Consider With Treatment Sequencing for Pediatric Atopic Dermatitis

This news content has been independently developed and is not endorsed by the American Academy of Dermatology.

Video content above is prompted by the following:

• When initiating treatment for a child with moderate AD, what factors influence your decision to start with certain therapies over others?
• Where do you see the biggest gap in the current treatment paradigm for pediatric AD, and how might ruxolitinib cream help fill that gap?
• For children with moderate disease who may not yet require systemic therapy (or who aren’t eligible), what advantages would a nonsteroidal, topical Janus kinase inhibitor offer over current options?
• How do you determine when to escalate or de-escalate treatment in pediatric AD, and where might ruxolitinib cream fit in that decision-making process?
• Looking ahead, do you think new topical treatments like ruxolitinib could reduce the need for systemic therapies in certain pediatric patients? Why or why not?